Individual meropenem epithelial lining fluid and plasma PK/PD target attainment

Author:

Rohani Roxane1ORCID,Yarnold Paul R.2ORCID,Scheetz Marc H.345ORCID,Neely Michael N.67ORCID,Kang Mengjia8ORCID,Donnelly Helen K.8ORCID,Dedicatoria Kay3,Nozick Sophie H.9,Medernach Rachel L.10,Hauser Alan R.910ORCID,Ozer Egon A.1011ORCID,Diaz Estefani12,Misharin Alexander V.8ORCID,Wunderink Richard G.8ORCID,Rhodes Nathaniel J.345ORCID

Affiliation:

1. Discipline of Cellular and Molecular Pharmacology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA

2. Optimal Data Analysis, LLC, Chicago, Illinois, USA

3. Department of Pharmacy Practice, Midwestern University, Chicago College of Pharmacy, Downers Grove, Illinois, USA

4. Pharmacometrics Center of Excellence, Midwestern University, Downers Grove, Illinois, USA

5. Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA

6. Laboratory of Applied Pharmacokinetics and Bioinformatics, The Saban Research Institute, Children’s Hospital of Los Angeles, Los Angeles, California, USA

7. Keck School of Medicine, University of Southern California, Los Angeles, California, USA

8. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

9. Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

10. Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

11. Center for Pathogen Genomics and Microbial Evolution, Havey Institute for Global Health, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

12. Robert H. Lurie Comprehensive Cancer Research Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

Abstract

ABSTRACT It is unclear whether plasma is a reliable surrogate for target attainment in the epithelial lining fluid (ELF). The objective of this study was to characterize meropenem target attainment in plasma and ELF using prospective samples. The first 24-hour T >MIC was evaluated vs 1xMIC and 4xMIC targets at the patient (i.e., fixed MIC of 2 mg/L) and population [i.e., cumulative fraction of response (CFR) according to EUCAST MIC distributions] levels for both plasma and ELF. Among 65 patients receiving ≥24 hours of treatment, 40% of patients failed to achieve >50% T >4xMIC in plasma and ELF, and 30% of patients who achieved >50% T >4xMIC in plasma had <50% T >4xMIC in ELF. At 1xMIC and 4xMIC targets, 3% and 25% of patients with >95% T >MIC in plasma had <50% T >MIC in ELF, respectively. Those with a CRCL >115 mL/min were less likely to achieve >50%T >4xMIC in ELF ( P < 0.025). In the population, CFR for Escherichia coli at 1xMIC and 4xMIC was >97%. For Pseudomonas aeruginosa , CFR was ≥90% in plasma and ranged 80%–85% in ELF at 1xMIC when a loading dose was applied. CFR was reduced in plasma (range: 75%–81%) and ELF (range: 44%–60%) in the absence of a loading dose at 1xMIC. At 4xMIC, CFR for P. aeruginosa was 60%–86% with a loading dose and 18%–62% without a loading dose. We found that plasma overestimated ELF target attainment inup to 30% of meropenem-treated patients, CRCL >115 mL/min decreased target attainment in ELF, and loading doses increased CFR in the population.

Funder

HHS | National Institutes of Health

Midwestern University

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3